Nicolás M. S. Gálvez

Author

Millennium Institute on Immunology and Immunotherapy ORCID

Also Known As

Gálvez, Nicolás M.S., N. Galvez, N.M.S Galvez, Nicolas M S Galvez, Nicolas M. S. Galvez, Nicolas M. S. Gálvez, Nicolas M.S. Galvez, Nicolás Gálvez, Nicolás M S Gálvez, Nicolás M. S. Gálvez

Publications

Citations

H-Index

Concepts

All Affiliations

Millennium Institute on Immunology and Immunotherapy Pontificia Universidad Católica de Chile Instituto de Salud Pública de Chile Sinovac Biotech La Jolla Institute for Immunology

About

Nicolás M. S. Gálvez is an author at Millennium Institute on Immunology and Immunotherapy specializing in cell transplantation, vaccine development, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	24
2	Immunology	1	1	24
3	Transplantation	1	1	24
4	Vaccine Development	1	1	24
5	Cell Transplantation	1	1	24

Nicolás M. S. Gálvez

Publications

591

Citations

H-Index

Page 1

	Year	Citations
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile Susan M. Bueno, Katia Abarca, Pablo A. González, Clinical Infectious Diseases	2021	109
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine Felipe Melo-González, Jorge A. Soto, Liliana A González, Frontiers in Immunology	2021	80
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine Luisa F. Duarte, Nicolás M. S. Gálvez, Carolina Iturriaga, Frontiers in Immunology	2021	67
Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial Susan M. Bueno, Katia Abarca, Pablo A. González,	2021	59
Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial Katia Abarca, Emma Rey-Jurado, Natalia Muñoz‐Durango, EClinicalMedicine	2020	54
Recombinant BCG Vaccines Reduce Pneumovirus-Caused Airway Pathology by Inducing Protective Humoral Immunity Jorge A. Soto, Nicolás M. S. Gálvez, Claudia A. Rivera, Frontiers in Immunology	2018	46
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern Bárbara M. Schultz, Felipe Melo-González, Luisa F. Duarte, mBio	2022	45
SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study Martín Dib, Nicole Le Corre, Catalina Ortiz, The Lancet Regional Health - Americas VaccinationTransplantationVaccine DevelopmentSolid Organ TransplantationImmunology	2022	24
BCG-Based Vaccines Elicit Antigen-Specific Adaptive and Trained Immunity against SARS-CoV-2 and Andes orthohantavirus Jorge A. Soto, Fabián E. Díaz, Angello Retamal‐Díaz, Vaccines	2022	18
Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults Constanza Méndez, Hernán F. Peñaloza, Bárbara M. Schultz, EBioMedicine	2023	18

Page 1